It came as AZ reported its third-quarter results, headlined by a 20% increase in revenues to $12.95 billion, which will be ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

The country contributed $5.05 billion in sales in the first nine months of 2024, or 13% of the British pharma’s total haul of ...

BofA analyst Jason Gerberry raised the firm’s price target on Jazz Pharmaceuticals (JAZZ ... trading at “highly depressed multiples,” yet offering mid-single digit sales and high-single digit bottom ...

Jefferies raised the firm’s price target on Verona Pharma (VRNA) to $45 from $38 and keeps a Buy rating on the shares. Ohtuvayre reported ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

On Wednesday, Zentalis Pharmaceuticals Inc (ZNTL) stock saw a modest uptick, ending the day at $3.92 which represents a slight increase of $0.21 or 5.66% from the prior close of $3.71. The stock ...

Mepsevii sales also jumped ... and justifies the increased price target to $95 based on revisions to their financial model. In other recent news, Ultragenyx Pharmaceutical (NASDAQ:RARE) Inc ...

HC Wainwright initiates Buy on Vanda Pharmaceuticals with an $18 price target, citing undervaluation, a strong product ...

The raised stock price target to $42 per American ... remains optimistic about continued sales growth and the drug's broad prescription base. Verona Pharma's recent financial performance and ...

The raised stock price target to $42 per American Depositary ... Despite the net loss for Q3, the company remains optimistic about continued sales growth and the drug's broad prescription base. Verona ...